CK2—An Emerging Target for Neurological and Psychiatric Disorders
AbstractProtein kinase CK2 has received a surge of attention in recent years due to the evidence of its overexpression in a variety of solid tumors and multiple myelomas as well as its participation in cell survival pathways. CK2 is also upregulated in the most prevalent and aggressive cancer of brain tissue, glioblastoma multiforme, and in preclinical models, pharmacological inhibition of the kinase has proven successful in reducing tumor size and animal mortality. CK2 is highly expressed in the mammalian brain and has many bona fide substrates that are crucial in neuronal or glial homeostasis and signaling processes across synapses. Full and conditional CK2 knockout mice have further elucidated the importance of CK2 in brain development, neuronal activity, and behavior. This review will discuss recent advances in the field that point to CK2 as a regulator of neuronal functions and as a potential novel target to treat neurological and psychiatric disorders. View Full-Text
A printed edition of this Special Issue is available here.
Share & Cite This Article
Castello, J.; Ragnauth, A.; Friedman, E.; Rebholz, H. CK2—An Emerging Target for Neurological and Psychiatric Disorders. Pharmaceuticals 2017, 10, 7.
Castello J, Ragnauth A, Friedman E, Rebholz H. CK2—An Emerging Target for Neurological and Psychiatric Disorders. Pharmaceuticals. 2017; 10(1):7.Chicago/Turabian Style
Castello, Julia; Ragnauth, Andre; Friedman, Eitan; Rebholz, Heike. 2017. "CK2—An Emerging Target for Neurological and Psychiatric Disorders." Pharmaceuticals 10, no. 1: 7.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.